Hot Features
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, w... Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product consists of SVN-114 for the treatment of post-traumatic stress disorder; and SVN-015 for the treatment of stimulant use disorder. The company was formerly known as Graft Polymer (UK) Plc and changed its name to Solvonis Therapeutics plc in January 2025. Solvonis Therapeutics plc was incorporated in 2017 and is headquartered in London, the United Kingdom. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.02 | -9.75609756098 | 0.205 | 0.22 | 0.1825 | 18803981 | 0.20368637 | DE |
| 4 | -0.065 | -26 | 0.25 | 0.2505 | 0.179 | 31618532 | 0.21412557 | DE |
| 12 | -0.08 | -30.1886792453 | 0.265 | 0.33 | 0.179 | 32415054 | 0.2461483 | DE |
| 26 | -0.075 | -28.8461538462 | 0.26 | 0.33 | 0.179 | 34759384 | 0.25444898 | DE |
| 52 | 0.005 | 2.77777777778 | 0.18 | 0.395 | 0.179 | 51621890 | 0.28801655 | DE |
| 156 | 0.02 | 12.1212121212 | 0.165 | 0.395 | 0.12 | 45522559 | 0.26265179 | DE |
| 260 | 0.02 | 12.1212121212 | 0.165 | 0.395 | 0.12 | 45522559 | 0.26265179 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.